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BACKGROUND. Mxi1, an antagonist of c-Myc, maps to human chromosome 10q24-q25, a
region altered in a substantial fraction of prostate tumors. Mice de®cient for Mxi1 exhibit
signi®cant prostate hyperplasia. We studied the ability of Mxi1 to act as a growth suppressor
in prostate tumor cells.
METHODS. We infected DU145 prostate carcinoma cells with an Mxi1-expressing adenovirus
(AdMxi1) in vitro, and measured Mxi1 expression, cell proliferation, soft agar colony
formation, and cell cycle distribution. To explore mechanisms of Mxi1-induced growth arrest,
we performed gene expression analysis.
RESULTS. AdMxi1 infection resulted in reduced cell proliferation, reduced soft agar colony
formation, and a higher proportion of cells in the G2/M phase of the cell cycle. This G2/M
growth arrest was associated with elevated levels of cyclin B, and reduced levels of c-MYC
and MDM2.
CONCLUSIONS. The ability of AdMxi1 to suppress prostate tumor cell proliferation
supports a role for Mxi1 loss in the pathogenesis of a subset of human prostate cancers.
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INTRODUCTION
Prostate cancer is the most common cancer in
men, and is associated with signi®cant morbidity and
mortality. Approximately 200,000 cases of prostate
cancer are diagnosed and almost 40,000 men die from
prostate cancer in the United States each year [1].
Genetic alterations that contribute to the pathogenesis
of prostate tumors include activation of oncogenes and
inactivation of tumor suppressor genes. Characteristic
gains and losses of chromosomal material, which
likely include such genes, are also seen in many cases
of prostate cancer [2].
Ampli®cation or overexpression of the c-MYC
oncogene in many human prostate adenocarcinomas
has implicated it in the pathogenesis and progression
of prostate cancer [3±7]. Furthermore, c-MYC, which
encodes a transcription factor of the basic helix-loop-
helix/leucine zipper (bHLH/ZIP) family [8,9], is
ampli®ed, rearranged, or overexpressed in human
prostate cancer cell lines [10-13]. Retrovirally mediated
expression of MYC in combination with activated RAS
in the mouse urogenital sinus causes a high frequency
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of poorly differentiated prostate cancers in such mice
[14]. Chronic overexpression of c-MYC in transgenic
murine ventral prostate epithelial cells leads to the
development of epithelial cell abnormalities similar to
those seen in low-grade prostatic intraepithelial neo-
plasia in humans [15]. Finally, introduction of c-MYC
antisense transcripts or oligonucleotides into human
prostate cell lines both in vitro and in vivo results in
reduced cell viability and tumor size [16,17]. Although
the overall contribution of c-MYC to prostate cancer
development and progression remains uncertain [18],
these ®ndings clearly implicate increased c-MYC
expression in prostate cancer pathogenesis.
c-Myc regulates expression of growth-related genes,
stimulating cell proliferation and preventing cellular
differentiation [19]. Mxi1 is also a transcription factor
that belongs to the Mad family of Myc antagonists,
which encode proteins that are highly homologous to
c-Myc [20±22]. Mxi1 opposes the growth-promoting
activity of c-Myc by repressing transcription of c-Myc-
activated target genes [23±26]. Mxi1 inhibits the ability
of c-Myc to transform cells in vitro [23,27,28], and its
expression is associated with cellular differentiation
[20,29±31]. By counteracting c-Myc, Mxi1 functions as
a growth suppressor, resulting in reduced cell pro-
liferation in vitro [32]. If c-MYC overexpression plays a
role in the pathogenesis of prostate malignancies,
inactivation or loss of MXI1 might enhance the
proliferative effect of c-Myc and contribute to prostate
tumor pathogenesis.
Several lines of evidence point to a role for Mxi1 as a
potential growth suppressor in the prostate. Transfec-
tion of whole chromosome 10 to PC3 prostate cancer
cells reduces the tumorigenicity of these cells [33,34],
indicating the existence of growth suppressive gene(s)
on chromosome 10. We [35] and others [36,37] pre-
viously localized the human MXI1 gene to chromo-
some 10q24-q25. Deletions resulting in loss of alleles in
this region of chromosome 10 are observed in 30±50%
of human prostate tumors [18,38±42]. Furthermore,
inactivating mutations in the MXI1 coding sequence
have been described in some primary human prostate
tumors [43,44]. Finally, mxi1-knockout mice, which
have a tumorigenic phenotype, demonstrate striking
prostate hyperplasia [45]. The enhanced proliferation
of prostate epithelium in mice that lack Mxi1 indicates
a role for Mxi1 in normal prostate development, and
suggests its potential involvement in human prostate
neoplasia.
To better de®ne the function of MXI1 in prostate
carcinoma, we have examined the ability of an Mxi1-
expressing adenovirus to suppress human prostate
cancer cell proliferation. Our demonstration that
Mxi1 expression results in markedly decreased pro-
liferation of DU145 prostate cells indicates a role
for Mxi1 as a prostate growth suppressor, and sup-
ports the hypothesis that loss of Mxi1 activity plays a




DU145 cells, originally derived from a prostate
carcinoma brain metastasis, were obtained from the
American Type Culture Collection (ATCC, Rockville,
MD). DU145 cells are androgen-insensitive, and can
form colonies in soft agar [46]. Furthermore, these cells
have enhanced expression of c-MYC, as well as loss of
chromosome 10q [47], and do not have detectable
levels of MXI1 mRNA by Northern blot (Taj and
Wechsler, unpublished observations). Cells were
maintained in RPMI 1640 (Gibco BRL, Rockville,
MD) with 10% heat inactivated fetal bovine serum
(HIFBS), 1% penicillin/streptomycin and 1% L-gluta-




We cloned the human MXI1 cDNA into pAdRSV4
[48] to generate a human Mxi1-expressing adenovirus
(AdMxi1). The pAdRSV4 plasmid includes a consti-
tutive Rous Sarcoma Virus (RSV) promoter to ensure
high levels of expression, in an E1-deleted adenovirus
backbone. Since reliable, commercial anti-Mxi1 anti-
bodies are not available, we modi®ed the MXI1 cDNA
at its C-terminal end to contain coding sequence for
an in¯uenza hemagglutinin (HA) peptide epitope
(YPYDVPDYA). This HA-tagged protein could then
be detected using anti-HA antibodies. After DNA
sequencing to con®rm appropriate sequence and
orientation of the MXI1-HA cDNA, replication-incom-
petent AdMxi1 was prepared by the Virus Core
Facility at The University of Michigan, with con®rma-
tory PCR and western blot analysis performed at each
step. AdMxi1 was concentrated to a titer of 1 1012
particles/ml, and had a replication competent adeno-
virus (RCA) content of less than 10ÿ 9. Control viral
preparations included AdLacZ (containing the bacter-
ial b-galactosidase gene), and AdDE1 (``empty'' virus
with a deleted E1 region), both at titers of 1 1012
particles/ml. The titer of plaque forming units (pfu)
for each virus was estimated to be 1% of the particle
number.
Twenty-four hours before viral infection, 105 DU145
cells were plated in wells of a 6-well plate. AdMxi1,
AdLacZ or AdDE1 viral particles were suspended in
RPMI (with 1% penicillin/streptomycin (p/s) and 1%
glutamine (glut) but no HIFBS). Following aspiration
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of media from the cells, the viral suspension was added
in a total volume of 2 ml. After a 2 hr incubation, the
medium was replaced with RPMI containing 5%
HIFBS, 1% p/s, and 1% glut. Medium containing
10% HIFBS was replaced 16±18 hr later and every 2±3
day subsequently. To determine the optimal titer for
viral infection, DU145 cells were plated in wells of 24-
well plates, and infected with a range of AdLacZ titers
(MOI (multiplicity of infection) of 10±5000 pfu/cell).
Twenty-four hours after infection, cells were washed,
®xed with 2% formaldehyde/0.05% glutaraldehyde in
PBS, and exposed to the substrate X-gal (5-bromo-4-
chloro-3-indolyl-b-D-galactoside; Gibco BRL) at a con-
centration of 1 mg/ml in PBS with 5 mM potassium
ferricyanide, 5 mM potassium ferrocyanide, and 2 mM
MgCl2. After X-gal treatment, expression of b-galacto-
sidase results in a blue color, providing a visual
measure of the infection ef®ciency. More than 95% of
cells were blue at AdLacZ titers greater than 500 pfu/
cell, while uninfected DU145 cells showed no color.
Experiments were done at titers of 1250±1750 pfu/cell,
since lower titers of either virus (500±1000 pfu/cell)
yielded inconsistent differences in growth rate,
whereas higher titers (> 2500 pfu/cell) resulted in
nonspeci®c toxicity and reduced cell number (Taj and
Wechsler, unpublished observations). Because effects
of AdLacZ were essentially identical to those seen
with AdDE1, only results for infection with AdDE1 as a
negative control will be presented for clarity.
Western BlotAnalysis, Immunofluorescence,
andConfocalMicroscopy
DU145 cells were plated in 6-well plates at a
concentration of 70,000 cells/well. After 24 hr, cells
were infected by AdMxi1 at MOI's of 1,000±10,000
pfu/cell. Ninety-six hours following infection, cells
were harvested, washed, and subjected to three freeze-
thaw cycles. Protein lysates were sonicated, normal-
ized for total protein concentration, mixed with equal
volumes of 2 loading buffer, and boiled for 10 min at
95C. Samples were electrophoresed on a 12% acryla-
mide SDS gel, followed by transfer to PVDF mem-
brane (Bio-Rad, Hercules, CA). Mxi1-HA protein was
detected with a rabbit polyclonal anti-HA antibody
(Santa Cruz Biotechnology, Santa Cruz, CA), followed
by goat anti-rabbit IgG HRP (Jackson Immunoresearch
Laboratories, West Grove, PA). An HA-tagged Bcl-xS
protein (gift of G. Nunez) was used as a positive
control for the HA antibody, and an expected band of
approximately 22 kDa was observed (data not shown).
The Enhanced Chemiluminescence (ECL; Amersham-
Pharmacia, Buckinghamshire, England) system was
used for detection according to manufacturer's
instructions.
For microscopy studies, DU145 cells were grown
on glass cover slips coated with 0.01% poly-L-lysine
(Sigma, St. Louis, MO). After 24 hr, cells were infected
with AdMxi1 or AdLacZ. Two to four days after
infection, cells were cooled on ice for 10 min, washed
twice with PBS, and permeabilized with methanol for
7 min at ÿ 20C. After washing twice with PBS at 4C,
cells were incubated for 1 hr with a 1:100 dilution of
mouse monoclonal anti-HA antibody (12CA5; Roche,
Indianapolis, IN). Following three PBS washes, a 1:50
dilution (in PBS) of secondary antibody (¯uorescein-
conjugated, goat anti-mouse IgG; Roche) was added
to the cells for 1 hr. After three additional PBS
washes, Vectashield Mounting Medium (Vector Labs,
Burlingame, CA) was applied. Immuno¯uorescence
microscopy was performed using a Nikon Eclipse
E600 immuno¯uorescence microscope. Confocal laser
scanning microscopy was performed using a Bio-Rad
MRC600 confocal microscope in the Cell Biology
Laboratories Core Facility at The University of
Michigan.
Soft Agar ClonogenicAssay
The ability of uninfected and virally infected DU145
cells to form colonies in soft agar was determined by
minor modi®cation of a previously described proce-
dure [32]. Brie¯y, a 1:1 mixture of SeaPlaque agarose
and SeaKem ME agarose (FMC Bioproducts, Rock-
land, ME) was used. A 1.4% bottom layer of agarose in
RPMI medium (with HIFBS, penicillin/streptomycin,
and L-glutamine) in a 100 mm plate was overlaid with
105 infected or uninfected DU145 cells resuspended
in 0.8% agarose with RPMI (and additives). Tissue
culture medium was added atop the agarose layer,
and plates were incubated at 37C in 5% CO2. Medium
was replaced every 3±4 days to prevent drying.
Colonies were enumerated 14±21 days later. The soft
agar assay was performed three times, with duplicate
samples in each assay.
BrdUIncorporationAssay
DU145 cells (5 103 cells/well in a 96-well plate)
were infected in triplicate with increasing concentra-
tions of AdMxi1 and AdLacZ viruses as described
above. After 48 hr, 110 ml of BrdU labeling reagent
(1:1,000 dilution; Roche) was added to each well, and
cells were incubated for 2 hr at 37 in 5% CO2. The
labeling reagent was then replaced with 200 ml of
®xing/denaturing solution, and cells were incubated
for 30 min at 25C. Next, 100 ml of peroxidase-
conjugated anti-BrdU antibody (1:100 dilution; Roche)
was added, with incubation for 90 min at 25C. Cells
were washed three times, 100 ml of substrate solution
were added, and cells were incubated for 30 min at
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25C. Absorbances were ®rst measured at 370 nm
(reference wavelength 492 nm) with a SpectraMax
ELISA Plate Reader (Molecular Devices, Sunnyvale,
CA). After stopping the reactions with 25 ml of 1 M
H2SO4, absorbances were read at 450 nm (reference
wavelength 690 nm).
FlowCytometry
To evaluate DNA content and expression of Mxi1-
HA in infected DU145 cells, 100±400,000 cells were
washed in wash buffer (WB: phosphate buffered
saline pH 7.2 (PBS)/1% heat-inactivated fetal bovine
serum), and ®xed with 75% ice-cold ethanol for 2 hr
at ÿ 20C. Cells were washed with WB, suspended
in 0.25% Triton X-100 in WB for 5 min at 4C,
washed again, and resuspended at a concentration of
107 cells/ml. Primary antibody (1:500 rabbit anti-HA
(Roche)) was added for 30 min at 25C, followed by
washing with WB. Secondary antibody (donkey anti-
rabbit IgG/Cy3 (Jackson Immunoresearch Labora-
tories)) was added for a 30 min, 25C incubation,
followed by washing with WB. Cell pellets were
resuspended in propidium iodide solution (10 mg/ml
in PBS) and incubated for a minimum of 10 min. Flow
cytometry analysis for DNA content and ¯uorescence
was performed at the University of Michigan Flow
Cytometry Core Facility with a Coulter Elite ESP Cell
Sorter and accompanying analysis software.
GeneExpression Profiling
The expression levels of cell cycle related genes
were evaluated in AdMxi1 infected cells using the
GEArray nylon membrane cDNA miniarray System
(SuperArray, Bethesda, MD) according to manufac-
turers instructions. Brie¯y, mRNA was harvested from
AdMxi1- and AdDE1-infected cells with an Oligotex
Direct mRNA Kit (Qiagen, Valencia, CA). After RNA
quantitation, cDNA probes were prepared by RT-PCR
using GEA primer mix, [a-32P] dCTP and MMLV
Reverse Transcriptase. Following prehybridization,
labeled cDNA probes were hybridized to Pathway-
®nder-1 and Cellcycle-1 GEArray membranes at 68C
for 24 hr. After washing, relative transcript abundance
was detected with a Molecular Dynamics Storm
phosphorimager and quantitated using NIH Image.
Hybridizations with each cDNA probe were per-
formed twice.
Statistical Analysis
The two-tailed Student t test was used to assess
statistical signi®cance of differences among experi-





We assessed the effects of restoring Mxi1 expression
to DU145 prostate cancer cells that lack functional
Mxi1 expression. To avoid the inef®ciency and selec-
tion bias associated with plasmid transfection, and to
achieve high-level MXI1 expression in a large percen-
tage of cells, we constructed an E1-deleted (DE1),
replication-incompetent MXI1-expressing adenovirus
(AdMxi1). An empty E1-deleted adenovirus (AdDE1)
was used to control for adenoviral infection.
Mxi1-HA protein expression in AdMxi1-infected
DU145 cells was assessed by Western blot analysis
using an anti-HA antibody. A 36-kDa band corre-
sponding to the size of Mxi1-HA was seen in AdMxi1-
infected cell extracts at an MOI of 1,000 pfu/cell
(Fig. 1, lane 3). The intensity of this band is not
increased when 5,000 pfu/cell are used for infection
(lane 4). A band of reduced intensity is seen when as
few as 300 pfu/cell were used for infection (Taj and
Wechsler, unpublished observations). This HA-speci-
®c band is not present in control AdDE1-infected cells
(lane 2), or in uninfected control cells (data not shown).
Immuno¯uorescence microscopy was used to localize
the Mxi1-HA protein within infected cells. AdMxi1-
infected cells exhibited some cytoplasmic expression
and a pronounced speckled pattern of nuclear stain-
ing, consistent with the presence of Mxi1 in the
nucleus (Fig. 2a). Higher power visualization by
confocal laser microscopy con®rmed the clumped
distribution of nuclear Mxi1-HA in AdMxi1-infected
Fig. 1. A 36 kDa Mxi1-HA protein is expressed in AdMxi1-
infected DU145 cells. Lane 1, in vitro translated (IVT) Mxi1-HA
protein; Lane 2, cell lysate prepared from DU145 cells infected
three days previously with AdDE1;Lanes 3 and 4, cell lysates pre-
pared fromDU145cells infected threedayspreviously withAdMxi1
at the indicated titers. Mxi1-HA protein expression was detected
by western blot analysis using a rabbit anti-HA antibody.Mobility
of 42 and 31kDamarkers are indicated.
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cells (Fig. 2b). No staining was seen in uninfected or
AdDE1-infected cells. These studies indicate that
AdMxi1 infection of DU145 cells results in strong
expression of Mxi1 protein and transport into the
nucleus, where the distribution is consistent with
chromatin binding and presumably transcriptional
repression activity. The degree of high-level Mxi1-HA
expression in infected cells was con®rmed by ¯ow
cytometry with rabbit anti-HA antibodies, which
demonstrated that 75±80% of the AdMxi1-infected
cells express Mxi1-HA (see Fig. 5d).
DU145 Proliferation Is Suppressed
byAdenoviralMxi1
Mxi1 expression in DU145 cells by AdMxi1 infec-
tion is associated with a marked reduction in growth
rate in vitro (Fig. 3). Uninfected DU145 cells (Fig. 3a)
and control adenoviral vector AdDE1-infected cells
(Fig. 3b) double their numbers in 24 and 48 hr,
respectively, while AdMxi1-infected cells (Fig. 3b)
exhibit no appreciable proliferation up to 7 days
following infection. On any given day (except day 0),
uninfected DU145 cell counts were consistently 1.5±3
times greater than AdDE1-infected cell numbers,
indicating some nonspeci®c adenovirus-associated
toxicity. The growth inhibitory effect of AdMxi1 was
apparent and signi®cantly different (P<0.003) from
AdDE1 by the third day postinfection. The growth of
AdMxi1-infected cells remained suppressed through
day 7 (Fig. 3). After 7 days, a subset of AdMxi1-
infected cells began to grow at rates comparable to
AdDE1-infected cells, becoming con¯uent after 10±13
days. The AdMxi1-infected cells that escaped from
growth inhibition showed no residual Mxi1 expres-
sion by Western blot (data not shown).
A BrdU incorporation assay was performed to
determine whether the increased doubling time of
AdMxi1-infected cells was due to reduced cell proli-
feration. As shown in Figure 4, DU145 cells infected
with AdMxi1 show a statistically signi®cant decrease
in BrdU incorporation, compared with AdDE1-infec-
ted cells, at all viral titers tested.
To examine the potential of virally infected DU145
cells to form anchorage-independent colonies (a
measure of their transformation potential), cells were
grown in soft agar. The number of soft agar colonies
derived from uninfected DU145 cells was 285 (range
264±308). AdDE1-infected cells yielded 119 colonies
(range 108±136), consistent with nonspeci®c adeno-
viral toxicity (P 0.0004). Notably, the number of
colonies derived from AdMxi1-infected cells was
signi®cantly reduced by nearly 75%, to 31 colonies




To investigate the mechanism of reduced cell
proliferation associated with MXI1 expression, the
cell cycle distributions of control AdDE1- and AdMxi1-
infected DU145 cells were compared. In the control
AdDE1-infected DU145 cells, more than half of the
Fig. 2. Mxi1-HAproteindistribution inAdMxi1-infectedDU145cells.Three days after infectionofDU145 cellswithAdMxi1virus, immuno-
fluorescence (a)wasperformedusing amousemonoclonal anti-HA antibody (magnification 200).Confocalmicroscopy (b) shows the intra-
nuclear distribution of Mxi1-HA protein at a higher magnification (500x). Note that positive cells have some cytoplasmic fluorescence and
strikingpunctate nuclear fluorescence.
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cells are in G0/G1, 30.4% are in S phase, and 15.2% are
in G2/M (Fig. 5a). The pro®le of uninfected DU145
cells is similar to that shown for AdDE1-infected cells,
with similar percentages of cells in G0/G1 (58.1%;
P 0.10), S (22.8%; P 0.12), and G2/M (19.1%;
P 0.17). In contrast, in AdMxi1-infected DU145 cells,
a signi®cantly lower proportion (30.9%) are in G0/G1
(P 0.0006 compared with AdDE1), with a corre-
sponding relative increase in the number of cells in S
phase (37.6%; P 0.04) and G2/M (31.5%; P 0.01),
suggesting that AdMxi1 infection of DU145 cells
results in a G2/M block, as we have previously shown
in glioblastoma cells [32]. AdMxi1 does not appear to
induce apoptosis, since there is no increase in the
number of sub-G0/G1 cells. To con®rm the lack of
AdMxi1-induced apoptosis, we performed a TUNEL
assay with uninfected, AdDE1-infected, and AdMxi1-
infected DU145 cells. Using this light microscopy-
based qualitative technique, no signi®cant apoptosis
was detected in either uninfected or infected DU145
cells: fewer than 5% of cells demonstrated evidence of
apoptosis under all three conditions.
Since cyclin B regulates progression through G2/M,
we hypothesized that Mxi1 might alter the level of
Fig. 4. AdMxi1-infectedDU145 cells incorporate less BrdU than
AdDE1-infected cells. Forty-eight hours after infection with the
indicated viral titer of either AdDE1 or AdMxi1, cells were pulsed
with BrdU.BrdUincorporation is expressed as OD450 units. Unin-
fected (uninf)DU145cells showedameanBrdUincorporationof1.4
OD450 units (white bar), significantly greater than all infected cells
(P<0.004). BrdU incorporation in AdMxi1-infected cells (black
bars)was significantly reduced in comparisonwithAdDE1-infected
cells (shaded bars) at all titers (P-values: 0.009 at 500 pfu, 0.003 at
1000 pfu, 0.03 at 1500 pfu, 0.004 at 2000 pfu and 0.01 at 2500 pfu).
One representative experiment (of 3 performed) is shown, with
triplicate assayresults (SEM).
Fig. 3. AdMxi1-infectedDU145 cells exhibit growth suppression in vitro.Growth curves of uninfected DU145 prostate cells (a), or DU145
cells infected with AdDE1 (ö*ö) or AdMxi1 (ö~ö) during log phase of growth (day 0) are shown (b).Viable cells were harvested and
counted using a Coulter Counter on subsequent days to determine growth curves. AdMxi1-infected cell numbers were significantly lower
thanAdDE1-infectedcellnumbers fromday3^6 (P-values of 0.0006,0.002,0.003, and0.00005, respectively).The curves shownrepresent data
fromnine separate experiments (SEM), with infection titers of1250^1750 pfu/cell.
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cyclin B in comparison with controls, and that altered
cyclin B function might be the mechanism for the
observed G2/M block in AdMxi1-infected DU145
cells. Two-color ¯ow cytometric analysis was used to
examine the relationship between Mxi1 and cyclin B
expression in AdMxi1-infected cells. As indicated in
Figure 5, 46% of control AdDE1-infected cells express
cyclin B with only a 5% background of HA cells. In
contrast, 63% of AdMxi1-infected cells express cyclin
B, and of these, the majority are also positive for Mxi1-
HA expression. In fact, Mxi1-HA expression strongly
correlates with expression of cyclin B: 68.5 6.0%
of Mxi1-HA positive cells express cyclin B (double
positives, Fig. 5d, quadrant 2), as compared with only
19.7 5.4% of Mxi1-HA negative cells (Fig. 5d,
quadrant 4) (P 0.0001). These results suggest that
Mxi1 overexpression perturbs the normal cyclin B
expression pattern, and that this perturbation is ass-
ociated with an altered cell-cycle distribution and a
G2/M blockade.
Finally, as a starting point to explore other possible
downstream effectors of Mxi1-induced growth arrest,
we surveyed the levels of expression of a panel of cell
cycle-related genes in DU145 cells infected by AdMxi1
in comparison with AdDE1. With RNA from cells
infected 48 hr previously, densitometric analysis reve-
aled decreases in the intensity of both c-MYC (by 24%)
and MDM2 (by 26%) expression. Although the decr-
eases in c-MYC and MDM2 are relatively modest, they
are highly reproducible. In contrast, only minor changes
were observed with other genes in the panel (e.g.,
p53, p21, gadd45) for which no signi®cant alterations
were detected. The changes in these patterns of
expression were not observed when samples taken
120 hr postinfection were used (data not shown). Taken
together, these observations suggest that Mxi1-induced
Fig. 5. Flow cytometry analysis of AdDE1-infected (a,b), and AdMxi1-infected (c,d) DU145 cells 72 hr after infection. (a,c) Representative
cell cycleprofile asmeasuredby PI staining with estimatedpercentages of cells inG0/G1, S, andG2/Mis indicated.Dots indicate cell numbers,
dashedcurves are extrapolated fromdots, and shadedareas are computer-generatedestimates ofpercentage of cells invariousphases of the
cell cycle. (b,d) Two-color flowcytometric analysis for levels of cyclin B (abscissa) andMxi1-HA (ordinate). AdDE1-infected cells (b) have only
background levels of green fluorescence (5%) corresponding to the Mxi1-HA fluorochrome (quadrants 12), whereas 79% of AdMxi1-
infected cells (d) are HA-positive.Cyclin B (quadrants 24) is detectable in 46% of AdDE1-infected cells, and 63% of AdMxi1-infected cells.
Cyclin B is detectable in 76% of AdMxi1-infectedHA-positive cells (double positives, quadrant 2/quadrants 24), but in only13% of AdMxi1-
infectedHA-negative cells (quadrant 4/quadrants24).Thedata shownare fromonerepresentative experiment (of sixperformed);percen-
tages quoted in the textof Results aremeans (SEM) from six individual experiments.
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suppression of proliferation is mediated, at least in
part, by well-established regulators of the cell cycle.
DISCUSSION
Several lines of evidence suggest a potential role for
Mxi1 as a prostate growth suppressor. First, Mxi1
antagonizes c-Myc [23±28], which is overexpressed in
many cases of prostate cancer [3±7]. Second, deletions
or rearrangements of the chromosome 10 region to
which the MXI1 gene maps are common in prim-
ary prostate tumors [18,38±42]. While PTEN/MMAC1
[49,50], a chromosome 10q tumor suppressor gene, is
thought to play a fundamental role in prostate cancer
development, the relative proximity of MXI1 to PTEN/
MMAC1 suggests that concomitant MXI1 allelic loss
might play a cooperative role in prostate tumor
pathogenesis. Third, MXI1 coding sequence mutations
have been described in two separate series of prostate
tumors [43,44]. Finally, mxi1 knockout mice [45]
exhibit abnormally hypertrophic prostate glands, with
foci of enlarged and complex glandular structures,
hypercellular acini, dysplastic cells, and occasional
mitotic ®gures, supporting the notion that Mxi1 plays
a role in prostate development. Although they display
no overt prostate neoplastic changes, these mice do
spontaneously develop malignant lymphomas, indi-
cating that Mxi1 may play a role as a tumor suppressor
gene in vivo [51]. The ability of Mxi1 to ``balance'' and
antagonize the activity of c-Myc, and the resultant
increased, relatively unopposed c-Myc activity in mxi1
knockout mice may contribute to these changes. The
goal of the present study was to test the effectiveness
of an Mxi1-expressing adenovirus in reducing pro-
liferation of prostate tumor cells in vitro.
We previously demonstrated the ability of Mxi1
to suppress growth of glioblastoma cells using an
inducible plasmid expression vector [32]. In the
present studies in human prostate cells, we used an
adenovirus vector containing the MXI1 cDNA to infect
DU145 cells. Because of the lack of an effective anti-
Mxi1 antibody, we tagged Mxi1 with an in¯uenza
hemagglutinin (HA) peptide epitope to enable detec-
tion; since results similar to those using a native
Mxi1 protein were obtained [32], the presence of a
C-terminal HA moiety apparently does not interfere
with Mxi1 function. Using AdMxi1, we achieved an
infection ef®ciency of 90±95%, with 75±80% of cells
expressing Mxi1 protein in the nucleus 48 hr after
infection. Enhanced Mxi1 expression led to a signi®-
cant reduction in growth rate during the ®rst week
post-infection. After 7 days, AdMxi1-infected cells
tended to grow at rates comparable to AdDE1-infected
cells, and after 10±13 days, con¯uent AdMxi1-infected
cells showed no residual Mxi1 expression by western
blot. The mechanism of outgrowth of Mxi1-HA nega-
tive cells is not known. While the outgrowth might
be due to the recovery and emerging predominance
of a minimal subset of uninfected cells, it could also
be related to loss of the ability of infected cells to
express the Mxi1-HA protein, perhaps by promoter
methylation.
AdMxi1 infection of DU145 prostate carcinoma
cells led to a nearly 75% reduction in the number of
colonies in soft agar when compared to colonies from
cells infected with the control AdDE1 adenovirus.
Since anchorage-independent growth in soft agar
correlates with tumorigenicity in vivo, this ®nding
indicates that Mxi1 suppresses factors necessary for
tumor production. There was also a reduction in BrdU
incorporation in AdMxi1-infected cells that correlated
with the reduced proliferation induced by AdMxi1.
The observed reduction in proliferation was not due to
apoptosis, since we did not detect an increase in the
sub-G0/G1 peak by ¯ow cytometry or in apoptotic
nuclei using the TUNEL assay. However, using ¯ow
cytometry, we did detect an increased proportion of
cells in the S and G2/M phases of the cell cycle. This
observation of a G2/M arrest as one possible mech-
anism by which MXI1 suppresses proliferation is
intriguing, since we saw a similar Mxi1-dependent
effect in a completely different cell line (U87MG
glioblastoma) using a different method of expression
(transfection with an inducible MXI1 plasmid) of a
non-HA-tagged Mxi1 protein [32]. Notably, this effect
on the cell cycle is different from that produced with
the highly homologous Mad1 protein [52], suggesting
that these Myc antagonists may have different gene
targets.
In investigating the mechanism of the G2/M arrest,
we found increased levels of cyclin B after adenoviral
Mxi1 expression. Dephosphorylation of cyclin B is
required for transition through the G2/M phase of the
cell cycle. Perturbation of normal cyclin B levels in the
setting of Mxi1 overexpression may prevent exit from
this stage of the cell cycle. Indeed, elevated levels of
cyclin B have been described in G2/M arrest [53,54]. It
is not known whether Mxi1 expression directly results
in increased cyclin B expression, or whether cyclin B is
elevated indirectly as a result of the G2/M block. The
speci®c mechanisms for increased cyclin B expression
(e.g., whether it is transcriptionally or posttranscrip-
tionally mediated) remain to be elucidated. In addi-
tion, we observed reduced levels of c-MYC and MDM2
after adenoviral Mxi1 expression. The observed redu-
ction in c-MYC mRNA expression is consistent with
the previously described direct transcriptional repres-
sion of the c-Myc promoter by Mxi1 [55]. Since c-Myc
overexpression promotes proliferation and transi-
tion through G2/M, reduced c-Myc as seen in
Mxil SuppressesDU145 Prostate Cells 201
AdMxi1-infected cells may inhibit this progression.
Indeed, many of the effects of Mxi1 may result from
direct or indirect misregulation of c-Myc. Finally, since
Mdm2 negatively regulates p53-mediated growth
suppression, Mxi1-induced downregulation of MDM2
might enhance p53-mediated growth suppression
[56,57]. Whether this is a direct (i.e., transcriptional)
effect of Mxi1 overexpression, or merely a re¯ection
of an ongoing G2/M block is unclear at the present
time. The absence of changes in these patterns of
expression by 120 hr after infection with AdMxi1
may be attributable to transcriptional repression by
Mxi1 that occurs during a relatively short window of
time. Alternatively, a population of cells with reduced
Mxi1 expression may already begin to appear at this
time.
Alterations in levels of other cell cycle proteins in
the presence of Mxi1 overexpression remain to be
evaluated. For example, since c-Myc activates tran-
scription and expression of the cdc25A CDK-activat-
ing phosphatase [58], downregulation of this protein
by Mxi1 might also contribute to the observed cell
cycle arrest. Nevertheless, Mxi1-induced alterations in
cyclin B, c-Myc, and Mdm2 indicate their potential
involvement in G2/M growth arrest.
CONCLUSIONS
Prostate cancer, which is most common in later life,
arises as a result of a multistep process of oncogene-
activating and tumor suppressor gene-inactivating
events. It is likely that a number of cooperating genetic
lesions contribute to tumor development, with possi-
ble involvement of Mxi1 in a subset of tumors.
Whether Mxi1 is involved early or late in the process
is presently unknown. We have demonstrated prostate
cancer cell growth inhibition by AdMxi1, with result-
ant G2/M arrest, associated with increased expression
of cyclin B and reduced expression of c-Myc and
Mdm2. These ®ndings indicate a growth suppressor
role for Mxi1 in prostate cancer. The ability of adeno-
virus-mediated Mxi1 expression to reduce DU145
prostate cell proliferation provides a rationale for
future studies to develop in vivo methods of Mxi1
delivery as a strategy for reducing malignant prostate
cancer growth and progression.
ACKNOWLEDGMENTS
We thank K. Cherian (University of Michigan
Adenovirus Core) for help in viral production, and
M. KuKuruga (University of Michigan Flow Cytome-
try Core) for assistance in ¯ow cytometry analysis.
We appreciate the constructive input of L. Benson,
T. Carey, C. Dang, G, Nunez, K. Pienta, S. Wechsler,
and R. Wechsler-Reya.
This study was supported in part by An American
Society for Clinical Oncology Young Investigator
Award, the Strokes Against Cancer Foundation,
NICHHD Child Health Research Center Grant 1-P30-
HD28820-01, and NCI Prostate SPORE 1-P50-
CA69568S (to D.S.W.); a Howard Hughes Medical
Institute Research Training Fellowship for Medical
Students (to C.H.); an American Society for Clinical
Oncology Career Development Award, and NCI
1-PO1-CA75136-01A1 (to M.G.S.); and by the UM±
Comprehensive Cancer Center NIH CA46592, the
UM±Multipurpose Arthritic Center NIH AR20557
and the UM±BRCF Core Flow Cytometry facility.
REFERENCES
1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics,
1998. CA Cancer J Clin 1998;48:6±29.
2. Dong J-T, Isaacs WB, Isaacs JT. Molecular advances in prostate
cancer. Curr Opinion in Oncology 1997;9:101±107.
3. Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew
NM, Johnston B, Dodd JG, Matusik RJ. Expression of the c-myc
protooncogene in human prostatic carcinoma and benign
prostatic hyperplasia. Cancer Res 1986;46:1535±1538.
4. Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson CA.
Enhanced expression of the c-myc protooncogene in high-grade
human prostate cancers. Prostate 1987;11:327±337.
5. Fox SB, Persad RA, Royds J, Kore RN, Silcocks PB, Collins CC.
p53 and c-myc expression in stage A1 prostatic adenocarci-
noma: useful prognostic determinants? J Urol 1993;150:490±494.
6. Qian J, Jenkins RB, Bostwick DG. Detection of chromosomal
anomalies and c-myc gene ampli®cation in the cribriform
pattern of prostatic intraepithelial neoplasia and carcinoma by
¯uorescence in situ hybridization. Mod Pathol 1997;10:1113±
1119.
7. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of
c-myc oncogene ampli®cation and chromosomal anomalies in
metastatic prostatic carcinoma by ¯uorescence in situ hybridi-
zation. Cancer Res 1997;57:524±531.
8. Potter M, Marcu KB. The c-myc story: where we've been, where
we seem to be going. Curr Top Microbiol Immunol 1997;224:1±
17.
9. Facchini LM, Penn LZ. The molecular role of Myc in growth and
transformation: recent discoveries lead to new insights. FASEB J
1998;12:633±651.
10. Nag A, Smith RG. Ampli®cation, rearrangement, and elevated
expression of c-myc in the human prostatic carcinoma cell line
LNCaP. Prostate 1989;15:115±122.
11. Wolf DA, Kohlhuber F, Schulz P, Fittler F, Eick D. Transcrip-
tional down-regulation of c-myc in human prostate carcinoma
cells by the synthetic androgen mibolerone. Br J Cancer
1992;65:376±382.
12. Yamazaki H, Schneider E, Myers CE, Sinha BK. Oncogene
overexpression and de novo drug-resistance in human prostate
cancer cells. Biochim Biophys Acta 1994;1226:89±96.
13. Asadi FK, Shari® R. Effects of sex steroids on cell growth and
c-myc oncogene expression in LN-CaP and DU-145 prostatic
carcinoma cell lines. Int Urol Nephrol 1995;27:67±80.
14. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune
BK, Flanders KC, Scardino PT, Park SH. Transgenic models for
the study of prostate cancer. Cancer 1993;71:1165±1171.
202 Taj et al.
15. Zhang X, Lee C, Ng PY, Rubin M, Shabsigh A, Buttyan R.
Prostatic neoplasia in transgenic mice with prostate-directed
overexpression of the c-myc oncoprotein. Prostate 2000;43:278±
285.
16. Balaji KC, Koul H, Mitra S, Maramag C, Reddy P, Menon M,
Malhotra RK, Laxmanan S. Antiproliferative effects of c-myc
antisense oligonucleotide in prostate cancer cells: a novel
therapy in prostate cancer. Urology 1997;50:1007±1015.
17. Steiner MS, Anthony CT, Lu Y, Holt JT. Antisense c-myc
retroviral vector suppresses established human prostate cancer.
Hum Gene Ther 1998;9:747±755.
18. Isaacs WB, Bova GS. Prostate cancer. In: B. Vogelstein B, Kinzler
KW, editors. The genetic basis of human cancer. New York:
McGraw-Hill; 1998;653±660.
19. Dang CV. c-Myc target genes involved in cell growth,
apoptosis, and metabolism. Mol Cell Biol 1999;19(1):1±11.
20. Zervos AS, Gyuris J, Brent R. Mxi1, a protein that speci®cally
interacts with Max to bind Myc-Max recognition sites. Cell
1993;72:223±232.
21. Ayer DE, Kretzner L, Eisenman RN. Mad: a heterodimeric
partner for Max that antagonizes Myc transcriptional activity.
Cell 1993;72:211±222.
22. Hurlin PJ, Queva C, Koskinen PJ, Steingrimsson E, Ayer DE,
Copeland NG, Jenkins NA, Eisenman RN. Mad3 and Mad4:
novel Max-interacting transcriptional repressors that suppr-
ess c-myc dependent transformation and are expressed dur-
ing neural and epidermal differentiation. EMBO J 1995;14:
5646±5659.
23. Schreiber-Agus N, Chin L, Chen K, Torres R, Rao G, Guida P,
Skoultchi AI, DePinho RA. An amino-terminal domain of Mxi1
mediates anti-Myc oncogenic activity and interacts with a
homolog of the yeast transcriptional repressor SIN3. Cell
1995;80:777±786.
24. Rao G, Alland L, Guida P, Schreiber-Agus N, Chen K, Chin L,
Rochelle JM, Seldin MF, Skoultchi AI, DePinho RA. Mouse
Sin3A interacts with and can functionally substitute for the
amino-terminal repression of the Myc antagonist Mxi1.
Oncogene 1996;12:1165±1172.
25. Alland L, Muhle R, Hou H Jr, Potes J, Chin L, Schreiber-Agus N,
DePinho RA. Role for N-CoR and histone deacetylase in Sin3-
mediated transcriptional repression. Nature 1997;387:49±55.
26. O'Hagan RC, Schreiber-Agus N, Chen K, David G, Engelman
JA, Schwab R, Alland L, Thomson C, Ronning DR, Sacchettini
JC, Meltzer P, DePinho RA. Gene-target recognition among
members of the myc superfamily and implications for
oncogenesis. Nat Genet 2000;24:113±119.
27. Lahoz EG, Xu L, Schreiber-Agus N, DePinho RA. Suppression
of Myc, but not E1a, transformation activity by Max-associated
proteins, Mad and Mxi1. Proc Natl Acad Sci USA 1994;91:5503±
5507.
28. Schreiber-Agus N, Chin L, Chen K, Torres R, Thomson CT,
Sacchettini JC, DePinho RA. Evolutionary relationships and
functional conservation among vertebrate Max-associated
proteins: the zebra ®sh homolog of Mxi1. Oncogene 1994;9:
3167±3177.
29. Larsson LG, Bahram F, Burkhardt H, Luscher B. Analysis of the
DNA-binding activities of Myc/Max/Mad network complexes
during induced differentiation of U-937 monoblasts and F9
teratocarcinoma cells. Oncogene 1997;15:737±748.
30. Delgado MD, Lerga A, Canelles M, Gomez-Casares MT, Leon J.
Differential regulation of Max and role of c-Myc during
erythroid and myelomonocytic differentiation of K562 cells.
Oncogene 1995;10:1659±1665.
31. Queva C, Hurlin PJ, Foley KP, Eisenman RN. Sequential
expression of the MAD family of transcriptional repressors
during differentiation and development. Oncogene 1998;16(8):
967±977.
32. Wechsler DS, Shelly CA, Petroff CA, Dang CV. MXI1, a putative
tumor suppressor gene, suppresses growth of human glioblas-
toma cells. Cancer Res 1997;57:4905±4912.
33. Ichikawa T, Nihei N, Kuramochi H, Kawana Y, Killary AM,
Rinker Schaeffer CW, Barrett JC, Isaacs JT, Kugoh H, Oshimura
M, Shimazaki J. Metastasis suppressor genes for prostate
cancer. Prostate Suppl 1996;6:31±35.
34. Murakami YS, Albertsen H, Brothman AR, Leach RJ, White RL.
Suppression of the malignant phenotype of human prostate
cancer cell line PPC-1 by introduction of normal fragments of
human chromosome 10. Cancer Res 1996;56:2157±2160.
35. Wechsler DS, Hawkins AL, Li X, Jabs EW, Grif®n CA, Dang CV.
Localization of the human Mxi1 transcription factor gene
(MXI1) to chromosome 10q24-q25. Genomics 1994;21:669±672.
36. Edelhoff S, Ayer DE, Zervos AS, Steingrimsson E, Jenkins NA,
Copeland NG, Eisenman RN, Brent R, Disteche CM. Mapping
of two genes encoding members of a distinct subfamily of MAX
interacting proteins: MAD to human chromosome 2 and mouse
chromosome 6, and MXI1 to human chromosome 10 and mouse
chromosome 19. Oncogene 1994;9:665±668.
37. Shapiro DN, Valentine V, Eagle L, Yin X, Morris SW,
Prochownik EV. Assignment of the human MAD and MXI1
genes to chromosomes 2p12-p13 and 10q24-q25. Genomics
1994;23:282±285.
38. Brothman AR, Peehl DM, Patel AM, McNeal JE. Frequency and
pattern of karyotypic abnormalities in human prostate cancer.
Cancer Res 1990;50:3795±3803.
39. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW,
Schalken JA, Epstein JI, Isaacs WB. Allelic loss of chromosomes
16q and 10q in human prostate cancer. Proc Natl Acad Sci USA
1990;87:8751±8755.
40. Lundgren R, Mandahl N, Heim S, Limon J, Henrikson H,
Mitelman F. Cytogenetic analysis of 57 primary prostatic
adenocarcinomas. Genes Chromosomes Cancer 1992;4:16±24.
41. Ittmann M. Allelic loss on chromosome 10 in prostate adeno-
carcinoma. Cancer Res 1996;56:2143±2147.
42. Lacombe L, Orlow I, Reuter VE, Fair WR, Dalbagni G, Zhang
ZF, Cordon-Cardo C. Microsatellite instability and deletion
analysis of chromosome 10 in human prostate cancer. Int J
Cancer 1996;69:110±113.
43. Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB,
Prochownik EV. Mutation of the MXI1 gene in prostate cancer.
Nat Genet 1995;9:249±255.
44. Prochownik EV, Eagle Grove L, Deubler D, Zhu XL, Stephenson
RA, Rohr LR, Yin X, Brothman AR. Commonly occurring loss
and mutation of the MXI1 gene in prostate cancer. Genes
Chromosomes Cancer 1998;22:295±304.
45. Schreiber-Agus N, Meng Y, Hoang T, Hou H Jr, Chen K,
Greenberg R, Cordon-Cardo C, Lee HW, DePinho RA. Role of
Mxi1 in ageing organ systems and the regulation of normal and
neoplastic growth. Nature 1998;393:483±487.
46. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF.
Isolation of a human prostate carcinoma cell line (DU 145). Int J
Cancer 1978;21:274±281.
47. Bernardino J, Bourgeois CA, Muleris M, Dutrillaux AM, Malfoy
B, Dutrillaux B. Characterization of chromosome changes in
two human prostatic carcinoma cell lines (PC-3 and DU145)
using chromosome painting and comparative genomic hybri-
dization. Cancer Genet Cytogenet 1997;96:123±128.
Mxil Suppresses DU145 ProstateCells 203
48. Crystal RG. Transfer of genes to humans: early lessons and
obstacles to success. Science 1995;270:404±410.
49. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J,
Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC,
Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. PTEN,
a putative protein tyrosine phosphatase gene mutated in human
brain, breast, and prostate cancer. Science 1997;275:1943±1947.
50. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon
AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C,
Hu R, Swedlund B, Teng DH, Tavtigian SV. Identi®cation of a
candidate tumour suppressor gene, MMAC1, at chromosome
10q23.3 that is mutated in multiple advanced cancers. Nat
Genet 1997;15:356±362.
51. Foley KP, Eisenman RN. Two MAD tails: what the recent
knockouts of Mad1 and Mxi1 tell us about the MYC/MAX/
MAD network. Biochim Biophys Acta 1999;1423:M37±47.
52. Chen J, Willingham T, Margraf LR, Schreiber-Agus N, DePinho
RA, Nisen PD. Effects of the MYC oncogene antagonist, MAD,
on proliferation, cell cycling and the malignant phenotype of
human brain tumour cells. Nat Med 1995;1:638±643.
53. Maity A, Hwang A, Janss A, Phillips P, McKenna WG, Muschel
RJ. Delayed cyclin B1 expression during the G2 arrest following
DNA damage. Oncogene 1996;13:1647±1657.
54. Suzuki M, Hosaka Y, Matsushima H, Goto T, Kitamura T,
Kawabe K. Butyrolactone I induces cyclin B1 and causes G2/M
arrest and skipping of mitosis in human prostate cell lines.
Cancer Lett 1999;138:121±130.
55. Lee TC, Ziff EB. Mxi1 is a repressor of the c-Myc promoter
and reverses activation by USF. J Biol Chem 1999;274:595±
606.
56. Momand J, Zambetti GP, Olson DC, George D, Levine AJ.
The mdm-2 oncogene product forms a complex with the p53
protein and inhibits p53-mediated transactivation. Cell 1992;69:
1237±1245.
57. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP.
Ampli®cation and overexpression of the MDM2 gene in a
subset of human malignant gliomas without p53 mutations.
Cancer Res 1993;53:2736±2739.
58. Galaktionov K, Chen X, Beach D. Cdc25 cell-cycle phosphatase
as a target of c-myc. Nature 1996;382:511±517.
204 Taj et al.
